Adam Feuerstein Is A Skeptic Of Stem Cell Therapy

Loading...
Loading...

Adam Feuerstein was recently a guest on #PreMarket Prep, a daily trading idea radio show hosted by Joel Elconin and Dennis Dick.

TheStreet Senior Columnist Adam Feuerstein discussed Cytori Therapeutics Inc CYTX on the show.

Overall, Feuerstein was skeptical of stem cell therapy companies.

“I think it’s a very difficult area of drug development, it has not shown much promise,” Feuerstein said.

The columnist pointed out that another stem cell related company, Athersys, Inc. ATHX, was “blowing up” Friday because its stroke study had failed.

“I feel like these companies don’t really have very much going on, Cytori being among those,” according to Feuerstein.

Cytori Therapeutics traded at $1.11, down 2.63 percent, while Athersys fell over 35 percent Friday to $1.41.

Check out the full interview below. Feuerstein comes in at about the one-hour mark:

Posted In: ExclusivesTrading IdeasInterviewAdam FeuersteinTheStreet
We simplify the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Loading...